Strategic positioning for clinical trials in 2021

MyMD will commence a Phase 2 clinical trial of MYMD-1 in COVID19 associated depression in 2021. In addition, we expect to advance MYMD-1 into a phase 2 clinical trial for treatment of diabetes, rheumatoid arthritis, Sarcopenia (aging) and multiple sclerosis. We will also execute studies of Supera-CBD that will enable submission of an Investigational New Drug Application (IND) to the FDA for a Phase 1 clinical trial in epilepsy, addiction, autism and anxiety disorders.

We’re making news in the biotech pharmaceuticals industry

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Announces Synthetic Cannabinoid Patent for Treatment of Substance Addiction and Other Disorders

MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

MyMD Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study

MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study

All News

  • This field is for validation purposes and should be left unchanged.